Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | DRD3 | P35462 | 3/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10732157 | 0.94 | LTA4H (0.53) | DRD4DRD2DRD3KCNH2ALDH3A1 | |
| SCHEMBL11178061 | 0.94 | DRD4 (0.50) | DRD4DRD2DRD3KCNH2ALDH3A1 | |
| SCHEMBL1172364 | 0.93 | DRD4 (0.53) | DRD4DRD2DRD3KCNH2ALDH3A1 | |
| SCHEMBL7621718 | 0.91 | HRH3 (0.53) | DRD4DRD2DRD3KCNH2ALDH3A1 | |
| SCHEMBL6752147 | 0.91 | HRH3 (0.53) | DRD4DRD2DRD3KCNH2ALDH3A1 | |
| SCHEMBL7390013 | 0.91 | HRH3 (0.53) | DRD4DRD2DRD3KCNH2ALDH3A1 | |
| SCHEMBL10384122 | 0.91 | HRH3 (0.53) | DRD4DRD2DRD3KCNH2ALDH3A1 | |
| SCHEMBL689019 | 0.88 | DRD4 (0.52) | DRD4DRD2DRD3KCNH2ALDH3A1 | |
| SCHEMBL2530176 | 0.88 | KCNA3 (0.50) | DRD4DRD2DRD3ALDH1A1SMN1; SMN2 | |
| SCHEMBL17233002 | 0.86 | HRH3 (0.49) | DRD4DRD2DRD3KCNH2ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117105872-B | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2024-10-15 | — | — | CN | claimed |
| CN-117105872-A | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2023-11-24 | — | — | CN | claimed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250388581-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250312340-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. | 2025-10-09 | — | — | US | disclosed |
| US-12331052-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| US-20240415832-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-12-19 | — | — | US | disclosed |
| CN-117105872-B | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2024-10-15 | — | — | CN | disclosed |
| EP-4419523-A1 | NOVEL METHODS | Intra-Cellular Therapies, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556058-A | New method | 细胞内治疗公司 | 2024-08-27 | — | — | CN | disclosed |
| EP-0234045-A2 | A pyrazole oxime derivative and its production and use | NIHON NOHYAKU CO., LTD. (JP) | 1987-09-02 | — | — | EP | disclosed |
| EP-0044940-B1 | AMINO-DESOXY-1.4;3.6-DIANHYDRO-HEXITE NITRATES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | Dr. Willmar Schwabe GmbH & Co. (DE) | 1984-09-19 | — | — | EP | disclosed |
| US-4363805-A | TREATMENT OF CORONARY DISEASE | FIRMA WILLMAR SCHWABE (DE) | 1982-12-14 | — | — | US | disclosed |
| EP-0065864-A1 | Anti-hypertensive 1-substituted spiro (piperidine-oxobenzoxazines) | SYNTEX (U.S.A.) INC. (US) | 1982-12-01 | — | — | EP | disclosed |
| EP-0016310-B1 | MONOPHOSPHONATE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYMPHAR S.A. (CH) | 1982-09-22 | — | — | EP | disclosed |
| US-4349549-A | Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s | SYNTEX (U.S.A.) INC. (US) | 1982-09-14 | — | — | US | disclosed |
| EP-0049060-A1 | Imidazoles | BEECHAM GROUP PLC (GB) | 1982-04-07 | — | — | EP | disclosed |
| EP-0044940-A1 | Amino-desoxy-1.4;3.6-dianhydro-hexite nitrates, processes for their preparation and pharmaceutical compositions | Dr. Willmar Schwabe GmbH & Co. (DE) | 1982-02-03 | — | — | EP | disclosed |
| US-4268507-A | Monophosphonate compounds as hypoglycemic and/or antiartherogenic agents | SYMPHAR S.A. (CH) | 1981-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312340-A1 | METHODS OF TREATING NEUROPATHIC PAIN | GAP43, OPRK1, CNR2 | DRD4 2587/4885DRD2 1772/4885DRD3 1642/4885 |
| US-20250388581-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | DRD4 29/4885DRD2 7/4885DRD3 24/4885 |
| US-12331052-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | DRD4 37/4885DRD2 13/4885DRD3 27/4885 |
| US-20240415832-A1 | NOVEL METHODS | OPRK1, OPRD1, OPRM1 | DRD4 279/4885DRD2 258/4885DRD3 201/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | DRD4 3651/4885DRD2 3122/4885DRD3 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.